Citius Pharmaceuticals, Inc.
CTXR
$0.78
-$0.05-5.92%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -3.29% | 9.45% | 19.48% | -11.76% | 9.47% |
| Total Depreciation and Amortization | 798.39% | 49.76% | -26.07% | 2.19% | 2.05% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 48.05% | -6.76% | 8.38% | 4.18% | -8.89% |
| Change in Net Operating Assets | -39.39% | -926.40% | -80.45% | 45.66% | 16.60% |
| Cash from Operations | -9.49% | -119.75% | -19.10% | 3.94% | 20.07% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 23.48% | -- | -- | -- | -- |
| Cash from Investing | 23.48% | -- | -- | -- | -- |
| Total Debt Issued | -- | -100.00% | -- | -- | -- |
| Total Debt Repaid | -- | 100.00% | -- | -- | -- |
| Issuance of Common Stock | 32.19% | 50.86% | 202.07% | 34.64% | 2,939.08% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | 0.00% | -- | -- | -- |
| Repurchase of Preferred Stock | -- | 0.00% | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 32.19% | 37.71% | 230.93% | 34.64% | 168.70% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 288.87% | -130.30% | 664.65% | 50.10% | 85.32% |